Financials data is unavailable for this security.
View more
Year on year Fusion Antibodies PLC had revenues fall -60.84% from 2.90m to 1.14m, though the company grew net income from a loss of 2.60m to a smaller loss of 2.23m.
Gross margin | -3.96% |
---|---|
Net profit margin | -195.95% |
Operating margin | -201.41% |
Return on assets | -99.33% |
---|---|
Return on equity | -152.67% |
Return on investment | -147.47% |
More ▼
Cash flow in GBPView more
In 2024, Fusion Antibodies PLC increased its cash reserves by 514.87%, or 1.00m. Cash Flow from Financing totalled 2.77m or 243.84% of revenues. In addition the company used 1.77m for operations while cash from investing totalled 1.00k.
Cash flow per share | -0.0361 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.0188 |
---|---|
Tangible book value per share | 0.0188 |
More ▼
Balance sheet in GBPView more
Current ratio | 3.87 |
---|---|
Quick ratio | 3.09 |
Total debt/total equity | 0.024 |
---|---|
Total debt/total capital | 0.0234 |
More ▼